Resistell News:

Faster to the right antibiotic treatment - Resistell in Schweizerische Ärztezeitung

Faster to the right antibiotic treatment - Resistell in Schweizerische Ärztezeitung
Resistell News:

Faster to the right antibiotic treatment - Resistell in Schweizerische Ärztezeitung

How do you find the most effective antibiotic for a patient as quickly as possible? The start-up "Resistell" has developed a new type of test for antibiotic resistance. Read more about this test in Schwizerische Ärztezeitung.
Faster to the right antibiotic treatment - Resistell in Schweizerische Ärztezeitung
curves

Latest news

17th April 2019

Startup Champions Seed Night 2019

a thrilling evening for innovators in Switzerland
Resistell at CNN Money
15th April 2019

Resistell at CNN Money

Danuta selected as top four up-and-coming entrepreneurs who made the best pitch at the annual Startup Champions Seed Night. Watch us on CNN Money and see how we will take our startup to the next level.
11th April 2019

Join us at ECCMID 2019 in Amsterdam, 13 - 16 April 2019

We invite you to meet us in Amsterdam at ECCMID 2019 (13 - 16 April 2019) and learn more about our rapid AST approach, see the product and discuss the future cooperations. Meet us any time at the booth 1.107!
Resistell presents rapid AST startup at D.Day 2019 at CHUV
10th April 2019

Resistell presents rapid AST startup at D.Day 2019 at CHUV

D.Day 2019 – Discover what your neighbours are working on!
iMedPub Journals about Resistell's rapid AST
10th April 2019

iMedPub Journals about Resistell's rapid AST

“This process is one of the most rapid methods in this review and can be used to develop quantitative anti-biograms”, Puttaswamy et al., 2018, Archives of Clinical Microbiology, 9:3, 83 https://doi.org/10.4172/1989-8436.100083
2nd April 2019

CHUV on the list of the 10 Best Hospitals in the World

Well done to all our colleagues from CHUV Hospital, recently listed in the top 10 best hospitals in the world. Resistell is proud to develop the rapid AST with the support of CHUV Hospital. Thank you and congratulations!
28th March 2019

Resistell selected as one of 10 Winners of Venture Leaders Life Sciences

Resistell was selected as one of ten new startups have been selected for Venture Leaders Life Sciences 2019. Chosen from among the most-promising life sciences startups in Switzerland, the team will embark on a packed, week-long roadshow in Boston. The startups will also pitch at the Startup Champions Seed Night event in Lausanne on 11 April.
25th March 2019

Join us at The Economist Antimicrobial Resistance Summit on 26.03.2019 in London

"Enough time has been wasted issuing warnings about antibiotic resistance. The moment has come to do something about it" ~The Economist
18th March 2019

The 50 Swiss startups in which to invest in 2019

Bilan selected Resistell as one of the Top 50 Swiss startups in which to invest in 2019! We are proud to be on the prestigious list with our rapid AST technology!
Resistell presented the science behind the rapid AST method during the AMR Berlin 2019 conference
18th March 2019

Resistell presented the science behind the rapid AST method during the AMR Berlin 2019 conference

We thank everyone who visited our scientific presentation in Berlin at Novel Antimicrobials & AMR Diagnostics Conference (14-15.03.2019). We are looking forward to all new future partnerships and collaborations!
Meet us it Berlin at Novel Antimicrobials and AMR Diagnostics 2019
13th March 2019

Meet us it Berlin at Novel Antimicrobials and AMR Diagnostics 2019

We invite you to meet us in Berlin at Novel Antimicrobials & AMR Diagnostics Conference (14-15.03.2019). For more details please visit https://amr-conference.com
Resistell wins 3rd stage of VentureKick
27th December 2018

Resistell wins 3rd stage of VentureKick

The jury of industry experts and investors selected Resistell to receive the highest level of Venture Kick’s financial support to bring their businesses to market.
12th December 2018

Resistell closes the seed financing round

Resistell has closed an oversubscribed seed financing round. Lead Investor Occident Group AG, Hemex AG and six other private investors invested in the EPFL spin-off developing the world’s fastest phenotypic antibiotic susceptibility test.
11th November 2018

Resistell a finalist of the Swiss Technology Award 2018!

Resistell AG a finalist of the Swiss Technology Award 2018!